Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders

A vizsgálat adatai

Ki végzi

Novartis Pharmaceuticals

Azonosító

NCT05086744

A regiszteradat frissítve

2025. október 16.

Eredeti leírás

The main purpose of this study was to evaluate the efficacy and safety of iptacopan in participants with autoimmune benign hematological disorders such as primary immune thrombocytopenia and primary cold agglutinin disease.A teljes eredeti leírásKevesebb

An Open-label, Multi-center, Phase 2 Basket Study to Assess Efficacy, Safety and Pharmacokinetics of Iptacopan (LNP023) in Participants With Autoimmune Benign Hematological Disorders

The main purpose of this study was to evaluate the efficacy and safety of iptacopan in participants with autoimmune benign hematological disorders such as primary immune thrombocytopenia and primary cold agglutinin disease.

Bevonási feltételek: All Cohorts:; Written informed consent; Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infections was required and vaccination against Haemophilus influenzae infection is recommended prior to the start of treatment; Weight of at least 35 kg; Cohort 1 specific inclusion criteria:; Participants with a diagnosis of persistent or chronic primary ITP; Participants must have received at least 1 unique prior therapy administered with the intention to treat ITP; Sustained thrombocytopenia; Cohort 2 specific inclusion criteria:; Participants with a diagnosis of primary CAD; Participants must have received at least 1 unique prior therapy administered with the intention to treat CAD; Laboratory evidence of ongoing hemolysis; Sustained anemia.

Kizáró feltételek: Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days, whichever is longer; or longer if required by local regulations; Past or concomitant use of medications prohibited by the protocol; Presence or suspicion of any active infection within 14 days prior to first study drug administration; Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing of investigational drug and for 1 week after last iptacopan dose; Severe concurrent comorbidities of unstable medical conditions; Cohort 1 specific exclusion criteria:; No ITP-directed background therapy permitted, with the exception of either a thrombopoietin receptor agonist or low-dose corticosteroid, as long as stable dosage for at least 4 weeks prior to first iptacopan dose; No CAD-directed background therapy permitted; History of primary or secondary immunodeficiency, including a positive HIV test result; Chronic infection with Hepatitis B or C virus; History of recurrent invasive infections caused by encapsulated organisms, including Neisseria meningitidis, Streptococcus pneumoniae, or Haemophilus influenzae; Any medical condition deemed likely to interfere with the participant's participation in the study; Any malignant disease diagnosed within the past 5 years, with the exception of localized non-melanoma skin cancer, in situ cervical cancer, or, for CAD, a low-grade lymphoproliferative disorder; History of bone marrow/hematopoietic stem cell or solid organ transplantation; Active severe bleeding or history of intracranial hemorrhage; Liver disease, or liver injury as indicated by abnormal liver function tests; Secondary ITP, as may arise in the setting of certain autoimmune disorders, immunodeficiency syndromes, infections, malignancies, and drug treatments; Secondary cold agglutinin syndrome, as may arise in the setting of certain infections, autoimmune disorders, and malignancies (with the exception of a low-grade lymphoproliferative disorder); All cohorts:; Known or suspected hereditary or acquired complement deficiency; Abnormal coagulation screening labs; Cohort 2 specific exclusion criteria:.

ClinicalTrials.gov NCT05086744